Innova Biosciences Introduces Range of Conjugated Antibodies
Innova Biosciences has launched a range of conjugated antibodies. The unique range leverages Innova’s Lightning-Link and InnovaCoat bioconjugation technologies, to provide customers with antibodies conjugated to an extensive range of enzymes, fluorescent dyes and colloidal gold, for improved flexibility in experimental design.
The new range comprises 200 antibodies to nearly 30 different cardiac biomarkers, each available directly conjugated to 24 different enzymes, fluorescent dyes or nanoparticles. Innova intends to expand the range into other key research areas in the near future, catering to an increasingly wide scientific audience.
In conjunction with the new range, Innova has launched a new corporate website, to provide customers with easier online ordering facilities, as well as access to a range of resources and support materials. The website also features an Antibody Conjugate Generator tool, which enables customers ordering from the new conjugated antibodies range to select any desired cardiac marker, antibody clone and label.
The online Conjugate Generator provides Innova’s customers with unprecedented flexibility, speed and conjugation possibilities, enabling highly tailored reagents to be created at a fraction of the cost of a custom conjugation project.
Dr Nick Gee, CEO at Innova, said: "This new range represents a progression for Innova from our range of bioconjugation kits. For the first time we are offering antibodies, capitalising on our conjugation technologies to create a powerful new tool for researchers.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...